MedTrace Logo

The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease

NCT04387279 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2020-05-13

No results posted yet for this study

Summary

The rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.

Conditions

  • COVID-19
  • Perception, Self
  • Facilities and Services Utilization

Interventions

OTHER

Interview

Surveys on medical use patterns and patient's perceptions about COVID-19

Sponsors & Collaborators

  • Yeungnam University College of Medicine

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    lead OTHER

Principal Investigators

  • Yoojin Lee, M.D. · Keimyung University Dongsan Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-24
Primary Completion
2021-03-30
Completion
2021-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387279 on ClinicalTrials.gov